Hematologic outcomes for studies grouped by baseline Hb levels
Citation . | Transfusion trigger or mean Hb at transfusion3-150 . | Baseline Hb . | Study arm . | No.enrolled . | No.evaluable . | EPO dose, U/kg/wk . | % response . | P . | Difference in % response (epo-control) . | Hb change (± SD) . | P . | Difference in Hb change (epo-control) . | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Start . | Final . | ||||||||||||
Mean/median baseline Hb no higher than 10 g/dL, adult patients | |||||||||||||
Silvestris et al11 | NA | NS3-151 | Control | 24 | 22 | 0 | 0.0 | ||||||
NS3-151 | Epoetin | 30 | 27 | 450 | 900 | 77.8 | 77.8 | ||||||
Oberhoff et al14 | NA | 10.33-152 | Control | 110 | 88 | 0 | 6.8 | ||||||
9.63-152 | Epoetin | 117 | 101 | ∼ 450 | 34.7 | .0001 | 27.9 | ||||||
Case et al9 | 8.2 | 9.8 | Control | 76 | 74 | 0 | 13.5 | 0.33 | |||||
8.2 | 9.5 | Epoetin | 81 | 79 | 450 | 58.2 | 44.7 | 2.3 | .0001 | 1.97 | |||
Henry et al12 | 8.5 | 9.5 | Control | 65 | 61 | 0 | 6.6 | 0.4 ± 1.73-153 | |||||
8.2 | 9.8 | Epoetin | 67 | 64 | 450 | 48.4 | < .0001 | 41.8 | 2.0 ± 2.33-153 | < .0001 | 1.60 | ||
Cascinu et al10 | 8.0 | 8.7 | Control | 50 | 49 | 0 | 2.0 | −0.6 | |||||
8.6 | Epoetin | 50 | 50 | 300 | 82.0 | 80.0 | 1.9 | 2.5 | |||||
Kurz et al13 | 8.0 | 9.85 | Control | 12 | 12 | 0 | 0.0 | 0.22 | |||||
9.88 | Epoetin | 23 | 23 | 450 | 900 | 56.5 | .001 | 56.5 | 3.3 | 3.08 | |||
Littlewood et al15 | NA | 9.7 | Control | 124 | 115 | 0 | 19.1 | 0.9 | |||||
9.9 | Epoetin | 251 | 244 | 450 | 900 | 70.5 | .001 | 51.4 | 2.5 | 1.60 | |||
Mean/median baseline Hb no higher than 10 g/dL, pediatric patients | |||||||||||||
Varan et al61 | 6.0 | 8.48 | Control | 17 | 17 | 0 | −0.07 | ||||||
8.5 | Epoetin | 17 | 17 | 450 | 1.71 | 1.78 | |||||||
Leon et al60 | 6.0 | 9.5 | Control | 25 | 25 | 0 | 0.1 | ||||||
9.8 | Epoetin | 25 | 25 | 750 | 72.0 | 2.6 | < .001 | 2.5 | |||||
Porter et al40 | 8.0 | 9.43-152 | Control | 12 | 10 | 0 | |||||||
9.73-152 | Epoetin | 12 | 10 | 450 | 900 | ||||||||
Mean/median baseline Hb between 10 and 12 g/dL, adult patients | |||||||||||||
Markman et al20 | 8.0 | 11.13-152 | Control | 46 | 40 | 0 | 40.0 | ||||||
11.53-152 | Epoetin | 17 | 16 | 350 | 87.5 | < .005 | 47.5 | ||||||
Dusenbery et al22 | 9.5 | 11.13-152 | Control | 61 | 61 | 0 | −0.8 | ||||||
10.33-152 | Epoetin | 15 | 15 | 1000 | 500 | 2.9 | .001 | 3.70 | |||||
Lavey and Dempsey21 | NA | 11.8 | Control | 20 | 20 | 0 | 5.0 | 0.0 ± 0.7 | |||||
11.9 | Epoetin | 20 | 20 | 900 | 450 | 80.0 | < .001 | 75.0 | 3.2 ± 1.78 | < .001 | 3.2 | ||
Wurnig et al24 | 8.5 | 10.5 | Control | 14 | 14 | 0 | |||||||
11 | Epoetin | 16 | 15 | 1200 | NS | ||||||||
Henke et al23 | NA | 12.3 | Control | 11 | 11 | 0 | 0.6 ± 1.4 | ||||||
10.9 | Epoetin 1 | 19 | 19 | 450 | 3.2 ± 1.6 | < .0001 | 2.6 | ||||||
11.4 | Epoetin 2 | 14 | 14 | 900 | 3.5 ± 1.2 | 2.9 | |||||||
Quirt et al26 | NA | 10.73-155 | Control | 28 | 27 | 0 | 0.6 | ||||||
10.93-155 | Epoetin | 28 | 27 | 450 | 900 | 1.6 | 1.0 | ||||||
ten Bokkel Huinink et al25 | 9.7 | 11.83-152 | Control | 34 | 33 | 0 | |||||||
12.03-152 | Epoetin 1 | 46 | 45 | 450 | 225 | ||||||||
11.63-152 | Epoetin 2 | 42 | 42 | 900 | 450 | ||||||||
Mean/median baseline Hb no lower than 12 g/dL, adult patients | |||||||||||||
Gamucci et al63 | NA | 12.7 | Control | 17 | 17 | 0 | − 1.5 ± 1.67 | ||||||
12.2 | Epoetin | 21 | 21 | 450 | 0.9 ± 1.32 | < .005 | 2.4 | ||||||
Sweeney et al62 | NA | 10.7 | Control | 24 | 24 | 0 | 0.0 | 0.29 | |||||
12.1 | Epoetin | 24 | 22 | 1000 | 500 | 45.5 | 45.5 | 1.55 | .0012 | 1.26 | |||
Del Mastro et al64 | 8.0 | 13.1 | Control | 31 | 31 | 0 | − 3.1 ± 1 | ||||||
13 | Epoetin | 31 | 31 | 450 | − 0.8 ± 1.4 | < .005 | 2.3 | ||||||
Thatcher et al27 | 8.5 | 13.43-152 | Control | 44 | 44 | 0 | 34.1 | −3.4 | |||||
8.6 | 13.73-152 | Epoetin 1 | 42 | 42 | 450 | 225 | 52.4 | < .05 | 18.3 | −3.2 | 0.2 | ||
8.0 | 13.63-152 | Epoetin 2 | 44 | 44 | 900 | 450 | 61.4 | .005 | 27.3 | −3.3 | 0.1 | ||
Welch et al65 | 8.5 | 12.8 | Control | 15 | 15 | 0 | −2.1 | ||||||
8.3 | 13 | Epoetin | 15 | 15 | 900 | 450 | −1.3 | 0.8 |
Citation . | Transfusion trigger or mean Hb at transfusion3-150 . | Baseline Hb . | Study arm . | No.enrolled . | No.evaluable . | EPO dose, U/kg/wk . | % response . | P . | Difference in % response (epo-control) . | Hb change (± SD) . | P . | Difference in Hb change (epo-control) . | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Start . | Final . | ||||||||||||
Mean/median baseline Hb no higher than 10 g/dL, adult patients | |||||||||||||
Silvestris et al11 | NA | NS3-151 | Control | 24 | 22 | 0 | 0.0 | ||||||
NS3-151 | Epoetin | 30 | 27 | 450 | 900 | 77.8 | 77.8 | ||||||
Oberhoff et al14 | NA | 10.33-152 | Control | 110 | 88 | 0 | 6.8 | ||||||
9.63-152 | Epoetin | 117 | 101 | ∼ 450 | 34.7 | .0001 | 27.9 | ||||||
Case et al9 | 8.2 | 9.8 | Control | 76 | 74 | 0 | 13.5 | 0.33 | |||||
8.2 | 9.5 | Epoetin | 81 | 79 | 450 | 58.2 | 44.7 | 2.3 | .0001 | 1.97 | |||
Henry et al12 | 8.5 | 9.5 | Control | 65 | 61 | 0 | 6.6 | 0.4 ± 1.73-153 | |||||
8.2 | 9.8 | Epoetin | 67 | 64 | 450 | 48.4 | < .0001 | 41.8 | 2.0 ± 2.33-153 | < .0001 | 1.60 | ||
Cascinu et al10 | 8.0 | 8.7 | Control | 50 | 49 | 0 | 2.0 | −0.6 | |||||
8.6 | Epoetin | 50 | 50 | 300 | 82.0 | 80.0 | 1.9 | 2.5 | |||||
Kurz et al13 | 8.0 | 9.85 | Control | 12 | 12 | 0 | 0.0 | 0.22 | |||||
9.88 | Epoetin | 23 | 23 | 450 | 900 | 56.5 | .001 | 56.5 | 3.3 | 3.08 | |||
Littlewood et al15 | NA | 9.7 | Control | 124 | 115 | 0 | 19.1 | 0.9 | |||||
9.9 | Epoetin | 251 | 244 | 450 | 900 | 70.5 | .001 | 51.4 | 2.5 | 1.60 | |||
Mean/median baseline Hb no higher than 10 g/dL, pediatric patients | |||||||||||||
Varan et al61 | 6.0 | 8.48 | Control | 17 | 17 | 0 | −0.07 | ||||||
8.5 | Epoetin | 17 | 17 | 450 | 1.71 | 1.78 | |||||||
Leon et al60 | 6.0 | 9.5 | Control | 25 | 25 | 0 | 0.1 | ||||||
9.8 | Epoetin | 25 | 25 | 750 | 72.0 | 2.6 | < .001 | 2.5 | |||||
Porter et al40 | 8.0 | 9.43-152 | Control | 12 | 10 | 0 | |||||||
9.73-152 | Epoetin | 12 | 10 | 450 | 900 | ||||||||
Mean/median baseline Hb between 10 and 12 g/dL, adult patients | |||||||||||||
Markman et al20 | 8.0 | 11.13-152 | Control | 46 | 40 | 0 | 40.0 | ||||||
11.53-152 | Epoetin | 17 | 16 | 350 | 87.5 | < .005 | 47.5 | ||||||
Dusenbery et al22 | 9.5 | 11.13-152 | Control | 61 | 61 | 0 | −0.8 | ||||||
10.33-152 | Epoetin | 15 | 15 | 1000 | 500 | 2.9 | .001 | 3.70 | |||||
Lavey and Dempsey21 | NA | 11.8 | Control | 20 | 20 | 0 | 5.0 | 0.0 ± 0.7 | |||||
11.9 | Epoetin | 20 | 20 | 900 | 450 | 80.0 | < .001 | 75.0 | 3.2 ± 1.78 | < .001 | 3.2 | ||
Wurnig et al24 | 8.5 | 10.5 | Control | 14 | 14 | 0 | |||||||
11 | Epoetin | 16 | 15 | 1200 | NS | ||||||||
Henke et al23 | NA | 12.3 | Control | 11 | 11 | 0 | 0.6 ± 1.4 | ||||||
10.9 | Epoetin 1 | 19 | 19 | 450 | 3.2 ± 1.6 | < .0001 | 2.6 | ||||||
11.4 | Epoetin 2 | 14 | 14 | 900 | 3.5 ± 1.2 | 2.9 | |||||||
Quirt et al26 | NA | 10.73-155 | Control | 28 | 27 | 0 | 0.6 | ||||||
10.93-155 | Epoetin | 28 | 27 | 450 | 900 | 1.6 | 1.0 | ||||||
ten Bokkel Huinink et al25 | 9.7 | 11.83-152 | Control | 34 | 33 | 0 | |||||||
12.03-152 | Epoetin 1 | 46 | 45 | 450 | 225 | ||||||||
11.63-152 | Epoetin 2 | 42 | 42 | 900 | 450 | ||||||||
Mean/median baseline Hb no lower than 12 g/dL, adult patients | |||||||||||||
Gamucci et al63 | NA | 12.7 | Control | 17 | 17 | 0 | − 1.5 ± 1.67 | ||||||
12.2 | Epoetin | 21 | 21 | 450 | 0.9 ± 1.32 | < .005 | 2.4 | ||||||
Sweeney et al62 | NA | 10.7 | Control | 24 | 24 | 0 | 0.0 | 0.29 | |||||
12.1 | Epoetin | 24 | 22 | 1000 | 500 | 45.5 | 45.5 | 1.55 | .0012 | 1.26 | |||
Del Mastro et al64 | 8.0 | 13.1 | Control | 31 | 31 | 0 | − 3.1 ± 1 | ||||||
13 | Epoetin | 31 | 31 | 450 | − 0.8 ± 1.4 | < .005 | 2.3 | ||||||
Thatcher et al27 | 8.5 | 13.43-152 | Control | 44 | 44 | 0 | 34.1 | −3.4 | |||||
8.6 | 13.73-152 | Epoetin 1 | 42 | 42 | 450 | 225 | 52.4 | < .05 | 18.3 | −3.2 | 0.2 | ||
8.0 | 13.63-152 | Epoetin 2 | 44 | 44 | 900 | 450 | 61.4 | .005 | 27.3 | −3.3 | 0.1 | ||
Welch et al65 | 8.5 | 12.8 | Control | 15 | 15 | 0 | −2.1 | ||||||
8.3 | 13 | Epoetin | 15 | 15 | 900 | 450 | −1.3 | 0.8 |
“Higher quality” trials in bold font; nonrandomized studies in italics. Data from Seidenfeld et al.3 (Tab15)
EPO indicates epoetin; and NS, not statistically significant.
A single entry is the transfusion trigger; multiple entries are mean Hb levels at transfusion.
Mean/median Hb level at baseline not specified, but enrollment limited to patients with Hb no higher than 10 g/dL.
The report provided only a median value, not a mean.
Change in Hb level calculated as change in hematocrit divided by 3.
Did not specify whether reported value is mean or median.